ストックスクリーナーアプリを入手
40.74
0.67%
0.27
アフターアワーズ：
41.32
0.58
+1.42%
前日終値:
$40.47
開ける：
$40.5
24時間の取引高:
2.88M
Relative Volume:
0.75
時価総額：
$17.41B
収益：
$2.31B
当期純損益:
$1.66B
株価収益率:
17.74
EPS:
2.297
ネットキャッシュフロー:
$827.02M
1週間 パフォーマンス:
+4.22%
1か月 パフォーマンス:
+3.88%
6か月 パフォーマンス:
+11.10%
1年 パフォーマンス:
+28.44%
1日の値動き範囲:
$40.49
$40.90
1週間の範囲:
$39.02
$40.90
52週間の値動き範囲:
$29.66
$41.70
Royalty Pharma Plc Stock (RPRX) Company Profile
名前
Royalty Pharma Plc
セクター
電話
(212) 883-0200
住所
110 EAST 59TH STREET, NEW YORK, NY
RPRX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
40.74 | 17.29B | 2.31B | 1.66B | 827.02M | 2.297 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-30 | 開始されました | Goldman | Buy |
| 2025-05-16 | 開始されました | Morgan Stanley | Overweight |
| 2024-06-03 | ダウングレード | UBS | Buy → Neutral |
| 2022-06-14 | 再開されました | UBS | Buy |
| 2022-05-13 | 開始されました | Scotiabank | Sector Outperform |
| 2022-04-27 | 開始されました | Goldman | Buy |
| 2022-04-14 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-04-06 | 再開されました | Morgan Stanley | Overweight |
| 2021-10-29 | アップグレード | Citigroup | Neutral → Buy |
| 2021-07-30 | 開始されました | Tigress Financial | Buy |
| 2020-11-09 | アップグレード | UBS | Neutral → Buy |
| 2020-07-14 | 開始されました | Evercore ISI | In-line |
| 2020-07-13 | 開始されました | BofA Securities | Buy |
| 2020-07-13 | 開始されました | Citigroup | Neutral |
| 2020-07-13 | 開始されました | Cowen | Outperform |
| 2020-07-13 | 開始されました | Goldman | Neutral |
| 2020-07-13 | 開始されました | JP Morgan | Neutral |
| 2020-07-13 | 開始されました | Morgan Stanley | Equal-Weight |
| 2020-07-13 | 開始されました | SunTrust | Buy |
| 2020-07-13 | 開始されました | UBS | Neutral |
すべてを表示
Royalty Pharma Plc (RPRX) 最新ニュース
Royalty Pharma (NASDAQ:RPRX) EVP Marshall Urist Sells 20,000 Shares of Stock - MarketBeat
Royalty Pharma PLC $RPRX Shares Sold by Y Intercept Hong Kong Ltd - MarketBeat
Royalty Pharma to buy royalty interest in Amgen’s Imdelltra for up to $950M - MSN
Mitsubishi UFJ Trust & Banking Corp Sells 198,889 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Cullen Frost Bankers Inc. Raises Position in Royalty Pharma PLC $RPRX - MarketBeat
(RPRX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Jim Cramer on Royalty Pharma: "It's a Terrific Company" - Finviz
84,741 Shares in Royalty Pharma PLC $RPRX Bought by Oxbow Advisors LLC - MarketBeat
Jim Cramer on Royalty Pharma: “It’s a Terrific Company” - Insider Monkey
Jim Cramer Shared His Takes on These 16 Stocks - Insider Monkey
Baillie Gifford & Co. Trims Position in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma EVP Coyne sells shares worth $2.7 million By Investing.com - Investing.com Nigeria
Royalty Pharma EVP Coyne sells shares worth $2.7 million - Investing.com
Terrance Coyne Sells 69,582 Shares of Royalty Pharma (NASDAQ:RPRX) Stock - MarketBeat
Smart Money: Is UAMY stock a buy or sellGDP Growth & AI Enhanced Trade Execution Alerts - baoquankhu1.vn
Royalty Pharma's (NASDAQ:RPRX) Upcoming Dividend Will Be Larger Than Last Year's - simplywall.st
How Investors May Respond To Royalty Pharma (RPRX) Dividend Hike Amid Insider Sales And Results Countdown - Yahoo Finance
Royalty Pharma (RPRX) Valuation Check After Recent Share Pullback And Strong 1 Year Return - Yahoo Finance
Patient Capital Management LLC Boosts Stake in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma Dividend Hike Highlights Income Appeal And Undervaluation - Sahm
Insider Selling: Royalty Pharma (NASDAQ:RPRX) EVP Sells $790,400.00 in Stock - MarketBeat
Royalty Pharma to announce fourth quarter and full year 2025 financial results on February 11, 2026 - marketscreener.com
Royalty Pharma to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026 - The Globe and Mail
Royalty Pharma plc to Release Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026 - Quiver Quantitative
Sumitomo Mitsui Trust Group Inc. Buys 207,338 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma (NASDAQ:RPRX) Raised to "Strong-Buy" at Wall Street Zen - MarketBeat
Nordea Investment Management AB Acquires 120,004 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Latham Watkins Advises on Royalty Financing Agreement Between Teva and Royalty Pharma - Latham & Watkins LLP
Royalty Pharma announces planned legal leadership transition - MSN
Eastern Bank Boosts Stake in Royalty Pharma PLC $RPRX - MarketBeat
Aug Technicals: Will Royalty Pharma plc stock remain a Wall Street favoriteDollar Strength & High Win Rate Trade Alerts - moha.gov.vn
Marshall Urist Sells 20,000 Shares of Royalty Pharma (NASDAQ:RPRX) Stock - MarketBeat
Urist Marshall, evp at Royalty Pharma, sells $815k in shares By Investing.com - Investing.com Canada
Urist Marshall, evp at Royalty Pharma, sells $815k in shares - Investing.com Australia
Royalty Pharma Insider Sold Shares Worth $815,634, According to a Recent SEC Filing - marketscreener.com
Liquidity Mapping Around (RPRX) Price Events - Stock Traders Daily
Will Royalty Pharma plc stock remain a Wall Street favoriteNew Guidance & Safe Entry Trade Signal Reports - Bộ Nội Vụ
Royalty pharma reports record year for royalty funding market By Investing.com - Investing.com Nigeria
Royalty Pharma promises $500M to Teva for advancing vitiligo treatment - MSN
TEVA secures $500 million funding from Royalty Pharma for vitiligo drug - StreetInsider
Teva Taps Royalty Pharma For $500M To Advance Skin Disease Drug - Benzinga
TEVA Signs Deal With RPRX to Accelerate Development of Vitiligo Drug - Finviz
Royalty pharma reports record year for royalty funding market - Investing.com
Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Royalty Pharma reports $4.7 billion in transactions for 2025 - StreetInsider
Franklin Credit Management CorporationRoyalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference - FinancialContent
Park Avenue Securities LLC Makes New Investment in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma (NASDAQ:RPRX) Is Increasing Its Dividend To $0.235 - Yahoo Finance
Royalty Pharma and Teva’s $500 million IL-15 deal boosts AnaptysBio stock - Investing.com Nigeria
Royalty Pharma provides up to $500 million for TEVA vitiligo drug - StreetInsider
Royalty Pharma And Teva Broaden Collaboration To Advance Potential Vitiligo Treatment - Nasdaq
Royalty Pharma Plc (RPRX) 財務データ
収益
当期純利益
現金流量
EPS
2.09%
0.48%
大文字化:
|
ボリューム (24 時間):